Ameritas Advisory Services LLC Invests $42,000 in Alnylam Pharmaceuticals, Inc. $ALNY

Ameritas Advisory Services LLC acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter, according to its most recent 13F filing with the SEC. The firm acquired 128 shares of the biopharmaceutical company’s stock, valued at approximately $42,000.

A number of other large investors also recently modified their holdings of the company. SVB Wealth LLC purchased a new position in Alnylam Pharmaceuticals in the first quarter valued at approximately $27,000. Bessemer Group Inc. raised its holdings in Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 69 shares during the period. Washington Trust Advisors Inc. raised its stake in shares of Alnylam Pharmaceuticals by 53.5% in the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 61 shares during the period. Larson Financial Group LLC raised its stake in shares of Alnylam Pharmaceuticals by 77.7% in the 1st quarter. Larson Financial Group LLC now owns 199 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 87 shares during the period. Finally, Geneos Wealth Management Inc. raised its stake in shares of Alnylam Pharmaceuticals by 372.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 175 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ALNY shares. Canaccord Genuity Group raised their target price on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Barclays raised their price objective on Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the company an “overweight” rating in a research report on Friday, August 1st. Needham & Company LLC raised their target price on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the company a “buy” rating in a report on Thursday, July 31st. Chardan Capital raised their target price on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a “buy” rating in a report on Friday, August 1st. Finally, Royal Bank Of Canada raised their target price on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an “outperform” rating in a report on Friday, September 19th. Twenty-four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $457.08.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $464.95 on Tuesday. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $484.21. The business has a 50 day simple moving average of $452.27 and a 200-day simple moving average of $347.50. The company has a market capitalization of $60.95 billion, a price-to-earnings ratio of -188.24 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm had revenue of $773.69 million during the quarter, compared to analyst estimates of $633.54 million. During the same quarter in the previous year, the firm earned ($0.13) earnings per share. The firm’s revenue for the quarter was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 8,924 shares of the business’s stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $4,034,094.20. Following the completion of the sale, the chief executive officer owned 65,409 shares of the company’s stock, valued at $29,568,138.45. This represents a 12.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the business’s stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,103,454.05. Following the sale, the executive vice president directly owned 25,231 shares of the company’s stock, valued at approximately $11,405,673.55. This represents a 8.82% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 98,144 shares of company stock worth $44,160,261. 1.20% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.